ACADIA Pharmaceuticals Inc.
ACADAcadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Drugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ACAD Earnings Report
EPS Est: $0.06 | FQ end 2026-06 | Call: 2026-08-04 15:00:00
How ACAD's past catalysts played out
ACP-204
Lewy Body Dementia Psychosis
Pimavanserin 34 mg
Dementia-related Psychosis
Trofinetide
Rett Syndrome
Pimavanserin tartrate (ACP-103)
Parkinson's Disease Psychosis
Carbetocin
Hyperphagia in Prader-Willi Syndrome
Pimavanserin
Agitation and Aggression in Alzheimer's Disease
pimavanserin tartrate
Parkinson's Disease Psychosis
ACP-103
Hallucinations
ACP-104
Schizophrenia
ACP-044 Dose A
Acute Postoperative Pain
ACP-211
Major Depressive Disorder (MDD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | - | - |
Pimavanserin 34 mg | Phase 3 | Dementia-related Psychosis | - | - |
Trofinetide | Phase 3 | Rett Syndrome | - | - |
Pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis | - | - |
Carbetocin | Phase 3 | Hyperphagia in Prader-Willi Syndrome | - | - |
Pimavanserin | Phase 3 | Agitation and Aggression in Alzheimer's Disease | - | - |
pimavanserin tartrate | Phase 3 | Parkinson's Disease Psychosis | - | - |
ACP-103 | Phase 2 | Hallucinations | - | - |
ACP-104 | Phase 2 | Schizophrenia | - | - |
ACP-044 Dose A | Phase 2 | Acute Postoperative Pain | - | - |
ACP-211 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Parkinson's Disease Psychosis
2 drugs in this indication
Acute Postoperative Pain
1 drug in this indication
Agitation and Aggression in Alzheimer's Disease
1 drug in this indication
Rett Syndrome
1 drug in this indication
Hallucinations
1 drug in this indication
Schizophrenia
1 drug in this indication
Lewy Body Dementia Psychosis
1 drug in this indication
Hyperphagia in Prader-Willi Syndrome
1 drug in this indication
Adjunctive Treatment of Major Depressive Disorder
1 drug in this indication
Dementia-related Psychosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ACADIA Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in ACADIA Pharmaceuticals Inc.'s (ACAD) pipeline across Phase 3, Phase 2. Its lead program is ACP-204 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACADIA Pharmaceuticals Inc.'s next FDA catalyst?→
ACADIA Pharmaceuticals Inc.'s (ACAD) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACAD biotech catalysts?→
Add ACAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACADIA Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.